[go: up one dir, main page]

NZ746125B2 - Pharmaceutical compositions comprising an anti-retroviral drug and a pharmacokinetic enhancer - Google Patents

Pharmaceutical compositions comprising an anti-retroviral drug and a pharmacokinetic enhancer Download PDF

Info

Publication number
NZ746125B2
NZ746125B2 NZ746125A NZ74612517A NZ746125B2 NZ 746125 B2 NZ746125 B2 NZ 746125B2 NZ 746125 A NZ746125 A NZ 746125A NZ 74612517 A NZ74612517 A NZ 74612517A NZ 746125 B2 NZ746125 B2 NZ 746125B2
Authority
NZ
New Zealand
Prior art keywords
piperine
trans
combination
cis
oral
Prior art date
Application number
NZ746125A
Other versions
NZ746125A (en
Inventor
Jeevan Ghosalkar
Kalpana Joshi
Geena Malhotra
Preeti Raut
Original Assignee
Cipla Limited
Filing date
Publication date
Application filed by Cipla Limited filed Critical Cipla Limited
Priority claimed from PCT/IN2017/050046 external-priority patent/WO2017138022A1/en
Publication of NZ746125A publication Critical patent/NZ746125A/en
Publication of NZ746125B2 publication Critical patent/NZ746125B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses

Abstract

oral or injectable pharmaceutical composition is provided for treating diseases caused by retroviruses or hepatitis B viruses. The composition comprises a therapeutically effective amount of at least one anti-retroviral drug and a therapeutically effective amount of at least one pharmacokinetic booster or enhancer or derivative thereof. Methods and kits are also provided.

Claims (22)

We claim,
1. An oral or injectable pharmaceutical composition comprising a therapeutically effective amount of at least one anti-retroviral drug, which comprises (i) a nucleotide analog reverse-transcriptase inhibitor (NRTI) selected from the group comprising: tenofovir alafenamide fumarate, tenofovir disoproxil fumarate, adefovir and a combination thereof; or (ii) a protease inhibitor (PI) comprising darunavir, and a therapeutically effective amount of at least one pharmacokinetic booster or enhancer, which comprises piperine, tetrahydropiperine, cis-piperine, trans-piperine, cis,trans-piperine, trans,cispiperine, cis,cis-piperine, trans,trans-piperine or a combination thereof.
2. The oral or injectable pharmaceutical composition of claim 1, wherein (i) the at least one pharmacokinetic booster or enhancer reduces a dosing frequency of the at least one anti-retroviral drug that is indicated for administration to a patient; and (ii) the at least one pharmacokinetic booster or enhancer increases the bioavailability of the at least one anti-retroviral drug from about 10% to about 70%.
3. The oral or injectable pharmaceutical composition of claim 1 or 2, wherein (i) the at least one anti-retroviral drug further comprises a nucleoside reverse transcriptase inhibitor (NRTI), non-nucleoside reverse transcriptase inhibitor (NNRTI), , integrase inhibitor, fusion inhibitor, CCR5 inhibitor, monoclonal antibody, glycoprotein inhibitor or combinations thereof;.
4. The oral or injectable pharmaceutical composition of claim 3, wherein the nucleoside reverse transcriptase inhibitor (NRTI) comprising lamivudine, abacavir, zidovudine, emtricitabine, didanosine, stavudine, entecavir, apricitabine, censavudine, zalcitabine, dexelvucitabine, amdoxovir, elvucitabine, festinavir, racivir, stampidine or a combination thereof; a non-nucleoside reverse transcriptase inhibitor (NNRTI) comprising lersivirine, rilpivirine, efavirenz, etravirine, doravirine, dapivirine or a combination thereof; the protease inhibitor (PI) further comprises lopinavir, ritonavir, saquinavir, nelfinavir, amprenavir, indinavir, nelfinavir, atazanavir, lasinavir, palinavir, tirpranavir, fosamprenavir, tipranavir or a combination thereof; an integrase inhibitor comprising dolutegravir, elvitegravir, raltegravir, bictegravir, cabotegravir or a combination thereof; a fusion inhibitor comprising maraviroc, enfuvirtide, griffithsin, aplaviroc, vicriviroc, plerixafor, fostemsavir, albuvirtide or a combination thereof; a CCR5 inhibitor comprising aplaviroc, vicriviroc, maraviroc, cenicriviroc or a combination thereof; a monoclonal 65 antibody comprising ibalizumab; a glycoprotein inhibitor comprising sifuvirtide; or combinations thereof.
5. The oral or injectable pharmaceutical composition of any one of claims 1-4, wherein the ratio of the at least one anti-retroviral drug to the at least one pharmacokinetic booster or enhancer is from about 100:1 to about 1:1 by weight.
6. The oral or injectable pharmaceutical composition of claim 1, wherein the tenofovir disoproxil fumarate in the composition is from about 1 mg to about 300 mg.
7. The oral or injectable pharmaceutical composition of claim 1 or 6, wherein the tenofovir alafenamide fumarate in the composition is from about 1 to about 25 mg.
8. The oral or injectable pharmaceutical composition of claim 4, wherein the dolutegravir in the composition is from about 1 mg to about 50 mg.
9. The oral or injectable pharmaceutical composition of claim 4, wherein the darunavir in the composition is from about 1 mg to about 800 mg.
10. The oral or injectable pharmaceutical composition of claim 4, wherein (i) the elvitegravir in the composition is from about 1 mg to about 150 mg; and (ii) the raltegravir in the composition is from about 1 mg to about 400 mg.
11. The oral or injectable pharmaceutical composition of any one of claims 1-10, wherein the piperine is in the composition from about 0.5 mg to about 400 mg.
12. An oral or injectable pharmaceutical composition of any one of claims 1-11, further comprising one or more pharmaceutically acceptable excipients comprising carriers, diluents, fillers, binders, lubricants, glidants, disintegrants, bulking agents, flavorants or any combination thereof.
13. The oral or injectable pharmaceutical composition of any one of claims 1-12, wherein the oral composition is in the form of a tablet, mini-tablet, granules, sprinkles, capsules, sachets, powders, pellets, and the injectable composition is in the form of a solution, suspension, emulsion, lyophilized powder or in the form of a kit. 66
14. The oral or injectable pharmaceutical composition of any one of claims 1-13, wherein the oral or injectable pharmaceutical composition is for use in the treatment or prophylaxis of diseases caused by retroviruses.
15. The oral or injectable pharmaceutical composition of any one of claims 1-14, wherein the oral or injectable pharmaceutical composition is for use in the treatment of diseases caused by hepatitis B viruses.
16. Use of a pharmaceutical composition comprising (i) a therapeutically effective amount of at least one anti-retroviral drug or an antiviral drug which comprises (i) a nucleotide analog reverse- transcriptase inhibitor selected from the group comprising: tenofovir alafenamide fumarate, tenofovir disoproxil fumarate, adefovir and a combination thereof; or (ii) a protease inhibitor (PI) comprising darunavir; (ii) a therapeutically effective amount of at least one pharmacokinetic booster or enhancer, which comprises piperine, tetrahydropiperine, cis-piperine, trans-piperine, cis-trans piperine, trans,cis- piperine, cis,cis-piperine, trans,trans- piperine or a combination thereof,; and (iii) one or more pharmaceutically acceptable excipients comprising carriers, diluents, fillers, binders, lubricants, glidants, disintegrants, bulking agents, flavourants or any combination thereof, in the manufacture of a medicament for the treatment of diseases caused by retroviruses or hepatitis B viruses in a patient in need of such treatment.
17. The use according to claim 16, wherein the diseases caused by retroviruses comprises acquired immune deficiency syndrome or an HIV infection.
18. A method of making a pharmaceutical composition that enhances the bioavailability of an anti-retroviral drug, the method comprising: mixing a therapeutically effective amount of at least one anti-retroviral drug, which comprises (i) a nucleotide analog reverse- transcriptase inhibitor selected from the group comprising: tenofovir alafenamide fumarate, tenofovir disoproxil fumarate, adefovir and a combination thereof; or (ii) a protease inhibitor (PI) comprising darunavir, and a therapeutically effective amount of at least one pharmacokinetic booster or enhancer, which comprises piperine, tetrahydropiperine, cis-piperine, trans-piperine, cis-trans piperine, trans,cispiperine, cis,cis-piperine, trans,trans- piperine or a combination thereof, with one or more pharmaceutically acceptable excipients to make the pharmaceutical composition. 67
19. The method according to claim 18, wherein the at least one anti-retroviral drug further comprises a nucleoside reverse transcriptase inhibitor (NRTI) comprising lamivudine, abacavir, zidovudine, emtricitabine, didanosine, stavudine, entecavir, apricitabine, censavudine, zalcitabine, dexelvucitabine, amdoxovir, elvucitabine, festinavir, racivir, stampidine or a combination thereof; a non-nucleoside reverse transcriptase inhibitor (NNRTI) comprising lersivirine, rilpivirine, efavirenz, etravirine, doravirine, dapivirine or a combination thereof the protease inhibitor (PI) further comprises lopinavir, ritonavir, saquinavir, nelfinavir, amprenavir, indinavir, nelfinavir, atazanavir, lasinavir, palinavir, tirpranavir, fosamprenavir, tipranavir or a combination thereof; an integrase inhibitor comprising dolutegravir, elvitegravir, raltegravir, bictegravir, cabotegravir or a combination thereof; a fusion inhibitor comprising maraviroc, enfuvirtide, griffithsin, aplaviroc, vicriviroc, plerixafor, fostemsavir, albuvirtide or a combination thereof; a CCR5 inhibitor comprising aplaviroc, vicriviroc, maraviroc, cenicriviroc or a combination thereof; a monoclonal antibody comprising ibalizumab; a glycoprotein inhibitor comprising sifuvirtide; or combinations thereof.
20. A kit for treating disease caused by retroviruses or hepatitis B viruses, the kit comprising a therapeutically effective amount of at least one anti-retroviral drug which comprises: (i) a nucleotide analog reverse- transcriptase inhibitor selected from the group comprising: tenofovir alafenamide fumarate, tenofovir disoproxil fumarate, adefovir and a combination thereof; or (ii) a protease inhibitor (PI) comprising darunavir, and a therapeutically effective amount of at least one pharmacokinetic booster or enhancer, wherein the at least one anti-retroviral drug, which comprises piperine, tetrahydropiperine, cis-piperine, trans-piperine, cis-trans piperine, trans,cispiperine, cis,cis-piperine, trans,trans- piperine or a combination thereof, wherein the at least one anti-retroviral drug is in a separate composition from the at least one pharmacokinetic booster or enhancer.
21. A method of enhancing the bioavailability of an oral anti-retroviral drug, the method comprising: providing a therapeutically effective amount of at least one anti-retroviral drug which comprises (i) a nucleotide analog reverse- transcriptase inhibitor selected from the group comprising: tenofovir alafenamide fumarate, tenofovir disoproxil fumarate, adefovir and a combination thereof; or (ii) a protease inhibitor (PI) comprising darunavir, and providing a therapeutically effective amount of at least one pharmacokinetic booster or enhancer, which comprises piperine, tetrahydropiperine, cis- 68 piperine, trans-piperine, cis-trans piperine, trans,cis- piperine, cis,cis-piperine, trans,trans- piperine or a combination thereof.
22. The method of claim 21, wherein (i) the at least one anti-retroviral drug is in a first composition and the at least one pharmacokinetic booster or enhancer is in a second composition; or (ii) the at least one anti-retroviral drug and the at least one pharmacokinetic booster or enhancer is combined in one composition
NZ746125A 2017-02-01 Pharmaceutical compositions comprising an anti-retroviral drug and a pharmacokinetic enhancer NZ746125B2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IN201621005051 2016-02-12
IN201621032504 2016-09-23
IN201621040945 2016-11-30
PCT/IN2017/050046 WO2017138022A1 (en) 2016-02-12 2017-02-01 Pharmaceutical compositions comprising an anti-retroviral drug and a pharmacokinetic enhancer

Publications (2)

Publication Number Publication Date
NZ746125A NZ746125A (en) 2024-08-30
NZ746125B2 true NZ746125B2 (en) 2024-12-03

Family

ID=

Similar Documents

Publication Publication Date Title
RU2018132408A (en) PHARMACEUTICAL COMPOSITIONS CONTAINING ANTIRETROVIRAL MEDICINES AND IMPROVERS OF PHARMACOKINETICS
US11944611B2 (en) Capsid inhibitors for the treatment of HIV
US10654827B2 (en) Therapeutic compounds
JP2017203033A5 (en)
AU2013336491B2 (en) Pharmaceutical antiretroviral composition
US10059697B2 (en) Compounds and combinations for the treatment of HIV
RU2014150327A (en) COMPOSITIONS OF THE CENTER OF CRANIFICATION AND METHODS FOR PRODUCING AND USING THEM
HRP20240501T1 (en) PYRIDO[2,3-D]PYRIMIDINE DERIVATIVES AS HUMAN IMMUNODEFICIENCY VIRUS REPLICATION INHIBITORS
WO2016036759A1 (en) Methods of treating or preventing hiv in patients using a combination of tenofovir alafenamide and dolutegravir
US20190151307A1 (en) Methods of treating patients co-infected with a virus and tuberculosis
NZ746125B2 (en) Pharmaceutical compositions comprising an anti-retroviral drug and a pharmacokinetic enhancer
RU2019136678A (en) COMBINATION THERAPY FOR USE IN THE TREATMENT OF RETROVIRAL INFECTIONS
WO2017205585A1 (en) Combinations and uses treatments thereof
JP2020527570A (en) Combination drug therapy
JP2020517633A5 (en)
FI4171572T3 (en) DOLUTEGRAVIR-CONTAINING DISPERSIBLE TABLET FORMULATIONS
EP4076446B1 (en) N-(3-amino-3-oxopropyl)-2-[(1-methyl-4-nitro-1h-imidazol-5-yl)thio]benzamide and its use for treating hiv infection
US20190030025A1 (en) Fostemsavir for use in heavily treatment-experienced hiv-1 infected individuals
WO2018042332A1 (en) Combinations and uses and treatments thereof
WO2024151425A1 (en) Compounds and method for treating hiv infection
WO2018044853A1 (en) Combinations and uses and treatments thereof
US20250326779A1 (en) Anti-hiv compounds
US20190183901A1 (en) Combinations and uses and treatments thereof
WO2018044838A1 (en) Combinations and uses and treatments thereof
RU2018105352A (en) Betulin derivatives for the prevention or treatment of HIV infections